158 related articles for article (PubMed ID: 33527796)
1. Basiliximab Induction with Delayed Calcineurin Inhibitors for High-Risk Lung Transplant Candidates.
Kim HE; Paik HC; Jeong SJ; Park MS; Kim SY; Lee JG
Yonsei Med J; 2021 Feb; 62(2):164-171. PubMed ID: 33527796
[TBL] [Abstract][Full Text] [Related]
2. Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction.
Lange NW; Salerno DM; Sammons CM; Jesudian AB; Verna EC; Brown RS
Clin Transplant; 2018 Dec; 32(12):e13415. PubMed ID: 30276862
[TBL] [Abstract][Full Text] [Related]
3. A Single-Center Experience of the Optimal Initial Immunosuppressive Strategy for Preventing Early Acute Cellular Rejection in Orthotopic Heart Transplantation Associated With Renal Dysfunction.
Mundisugih J; Fernando H; Bergin P; Hare J; Kaye D; Leet A; McGiffin D; Taylor AJ
Prog Transplant; 2019 Dec; 29(4):327-334. PubMed ID: 31476958
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study.
Hashim M; Alsebaey A; Ragab A; Soliman HE; Waked I
Ann Hepatol; 2020; 19(5):541-545. PubMed ID: 32768592
[TBL] [Abstract][Full Text] [Related]
5. Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency.
Verna EC; Farrand ED; Elnaggar AS; Pichardo EM; Balducci A; Emond JC; Guarrera JV; Brown RS
Transplantation; 2011 Jun; 91(11):1254-60. PubMed ID: 21617588
[TBL] [Abstract][Full Text] [Related]
6. Induction Immunosuppressive Therapy Use in Deceased Donor Kidney Transplantation: 11-Year Experience in Veracruz, Mexico.
Martinez-Mier G; Soto-Miranda E; Avila-Pardo SF; Budar-Fernandez LF; Mateu-Rivera LJ; Mendez-Lopez MT; Trujillo-Martinez MF; Uscanga-Montesano A; Avila Y Falfan D
Transplant Proc; 2016 Mar; 48(2):600-4. PubMed ID: 27110011
[TBL] [Abstract][Full Text] [Related]
7. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression.
Cillo U; Bechstein WO; Berlakovich G; Dutkowski P; Lehner F; Nadalin S; Saliba F; Schlitt HJ; Pratschke J
Transplant Rev (Orlando); 2018 Jul; 32(3):142-150. PubMed ID: 29709248
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
[TBL] [Abstract][Full Text] [Related]
9. Basiliximab: a review of its use as induction therapy in renal transplantation.
Chapman TM; Keating GM
Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of thymoglobulin and basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function.
Chen G; Gu J; Qiu J; Wang C; Fei J; Deng S; Li J; Huang G; Fu Q; Chen L
Exp Clin Transplant; 2013 Aug; 11(4):310-4. PubMed ID: 23121641
[TBL] [Abstract][Full Text] [Related]
11. CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen.
Thibault G; Paintaud G; Legendre C; Merville P; Coulon M; Chasseuil E; Ternant D; Rostaing L; Durrbach A; Di Giambattista F; Büchler M; Lebranchu Y
Transpl Int; 2016 Feb; 29(2):184-95. PubMed ID: 26369526
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody.
Gonwa TA; Mai ML; Smith LB; Levy MF; Goldstein RM; Klintmalm GB
Clin Transplant; 2002 Apr; 16(2):144-9. PubMed ID: 11966785
[TBL] [Abstract][Full Text] [Related]
13. Induction Therapy With ATG Compared With Anti-IL2 Basiliximab in Low-Immunologic Risk Kidney Transplant Recipients.
Dedinská I; Graňák K; Vnučák M; Skálová P; Laca Ĺ; Krivuš J; Galajda P; Mokáň M
Transplant Proc; 2019 Dec; 51(10):3259-3264. PubMed ID: 31732198
[TBL] [Abstract][Full Text] [Related]
14. Initial data on basiliximab in critically ill children undergoing heart transplantation.
Ford KA; Cale CM; Rees PG; Elliott MJ; Burch M
J Heart Lung Transplant; 2005 Sep; 24(9):1284-8. PubMed ID: 16143246
[TBL] [Abstract][Full Text] [Related]
15. Basiliximab as maintenance immunosuppression in heart transplant recipients: A single pediatric center experience.
Chen TT; Greene MM; Everitt MD; Simpson KE
Pediatr Transplant; 2023 Mar; 27(2):e14438. PubMed ID: 36397270
[TBL] [Abstract][Full Text] [Related]
16. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
[TBL] [Abstract][Full Text] [Related]
18. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
Clark G; Walsh G; Deshpande P; Koffman G
Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
20. Influence of Induction Therapy Using Basiliximab With Delayed Tacrolimus Administration in Heart Transplant Recipients - Comparison With Standard Tacrolimus-Based Triple Immunosuppression.
Watanabe T; Yanase M; Seguchi O; Fujita T; Hamasaki T; Nakajima S; Kuroda K; Kumai Y; Toda K; Iwasaki K; Kimura Y; Mochizuki H; Anegawa E; Sujino Y; Yagi N; Yoshitake K; Wada K; Matsuda S; Takenaka H; Ikura M; Nakagita K; Yajima S; Matsumoto Y; Tadokoro N; Kakuta T; Fukushima S; Ishibashi-Ueda H; Kobayashi J; Fukushima N
Circ J; 2020 Nov; 84(12):2212-2223. PubMed ID: 33148937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
